North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 14 of 14
Details
UPD
sitematrix Changed from 0 to
17/11/2022 14:34:33
(DavidS )
UPD
FurtherInformation Changed from
100mg & 160mg powder for concentrate for solution for infusion
Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commis
17/11/2022 14:34:33
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) NIC ETA632
17/11/2022 14:34:33
(DavidS )
LDL
Link Added : NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer : https://www.nice.org.uk/guidance/ta632
17/11/2022 14:34:04
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) updated
30/01/2018 13:15:13
(DavidS )
UPD
Published from Draft Mode
27/10/2017 15:20:28
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) update
27/10/2017 15:20:19
(DavidS )
LDL
Link Added : NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane : https://www.nice.org.uk/guidance/ta458
26/10/2017 16:52:49
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) updated
26/10/2017 16:52:11
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) NICE TA458
26/10/2017 16:51:26
(DavidS )
UPD
Status Changed to | Hidden | Published
22/03/2017 15:10:45
(DavidS )
UPD
Published from Draft Mode
31/01/2017 14:35:10
(DavidS )
UPD
Trastuzumab emtansine (Kadcyla
®
) b
23/01/2017 10:34:33
(WhitehallJ )
UPD
Trastuzumab emtansine (Kadcyla
®
) build
28/11/2016 15:54:41
(DavidS )